(Date:7/2/2009)...honored in Washington, D.C. , , ARLINGTON, Tex...th Resources has received the Best Employers for ...ss Group on Health. , , (Logo: http://www.ne..., , The award recognizes the nation,s leading co...healthy workplace and for helping employees and th...
(Date:7/2/2009)... threat, expert says , , THURSDAY, July... certain species of wildlife, which need to be pro... , "Cancer is one of the leading health concern...of human deaths. But we now understand that cancer...hor Denise McAloose, chief pathologist for the Wil...
(Date:7/2/2009)...of neurons, another set wakes up: study , ...rmation about brain circuit activity may help expl...(zolpidem) walk, eat, talk on the phone and even d...ing it the next morning. , The drug has also be...to a conscious state. , In experiments with mic...
(Date:7/2/2009)...ssues need to be addressed in order to improve bio...r, according to a commentary published online July...e . , The biomarker pipeline to develop and eval...ation of promising biomarkers to detect cancers ea...iomarkers for cancer screening. , In the commen...
Breaking Medicine News(10 mins):Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Cancer Endangers Some Wildlife Species 2Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2(Date:6/28/2009)...O, Portugal, June 29 Data presente...eatment with the novel,once-daily anti-epileptic...ed,in a marked and sustained decrease in seizure ...from the one-year extension of a pivotal Eslicarba...the International Congress for Epilepsy in,Budape...
(Date:6/26/2009)...ed and New Genetic Mutations Acting Together-- , ...-- More pieces in the complex autism inheritance p...arch team including geneticists from The Children,...nsylvania School of Medicine and several collabor...rent genetic regions where rare copy number variat...
(Date:6/25/2009)...tent Covering ARIKACE for Once-Daily Treatment of ...ON, N.J., June 25 Cystic Fibrosis ...ate of the Cystic Fibrosis Foundation, has provide...ontinued development of ARIKACE(TM) (liposomal ami...treat Pseudomonas lung infections in cystic fibr...
(Date:6/24/2009)...ults of second Phase III study show highly signifi...ily function in fibromyalgia patients and confirm ... ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-F... -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ...ositive preliminary top-line results from the seco...
Breaking Medicine Technology:Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 6DNA replication behavior in complex organisms may foreshadow leaps in genomic discoveries 53 1Dominant cholesterol metabolism ideas challenged by new research 50 1Dominant cholesterol metabolism ideas challenged by new research 50 2Dominant cholesterol metabolism ideas challenged by new research 50 3Dominant cholesterol metabolism ideas challenged by new research 50 4Older climbers face uphill battle on Mount Everest 47 1Older climbers face uphill battle on Mount Everest 47 2Older climbers face uphill battle on Mount Everest 47 3Western diet linked to increased risk of colon cancer recurrence 44 1Western diet linked to increased risk of colon cancer recurrence 44 2...anned ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, .../IIa study presented today at the American Society...cago demonstrate the,clinical activity of cilengit...– a particularly aggressive form of brain tu...hibitor targeting the,tumor and its vasculature. ,...
...y evaluating a clinically relevant model of,normal...t capable,of abrogating the cytotoxic effect of er...PTISOME(tm) agent was generally well,tolerated in ...,profile similar to conventional vincristine , SOU...WIRE) --,Hana Biosciences (Nasdaq:HNAB), a biophar...
Other Medicine Technology:Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5...d approach to quality patient care., ,S/5 Anesthe...to anesthesia delivery. As part of the S/5 Anesthe...res, electronically controlled gas delivery and ag...mation management to create a truly integrated sys...
A non-adhering hydrogel sheet dressing for use on all partial and full thickness wounds (excluding 3rd degree burns.) Hydrogel sheet contains 96% water and 4% insoluble cross-linked polyethylene oxid
...reg; Esteem™ External Vacuum Therapy System ...en. Non-invasive and low cost vacuum therapy, coup...able outcome", makes it the ideal therapy for trea...acuum Therapy System causes penile rigidity that c...
... Harmony Special Peristaltic phacoemulsification s...e latest technology including individual programma...hird generation system features a front panel with... display for ease of use and viewing. Under contro...
Medicine Products: